Positions

Selected Publications

Academic Article

Year Title Altmetric
2022 Phase II study of myeloablative allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia in adults using fludarabine and total body irradiation 12 GyBone Marrow Transplantation.  57:1597-1599. 2022
2022 Hypomethylating agent/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemiaBritish Journal of Haematology.  198:e35-e37. 2022
2022 Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemiaLeukemia Research.  117. 2022
2022 Risk of Cytomegalovirus Infection with Post-Transplantation Cyclophosphamide in Haploidentical and HLA-Matched Unrelated Donor Transplantation 2022
2022 First report of novel heterozygous WRAP53 p.Ala522Glyfs*8 mutation associated dyskeratosis congenitaBritish Journal of Haematology.  196:e27-e29. 2022
2022 Safe and Effective Use of Imatinib to Treat Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia During Pregnancy.Journal of Adolescent and Young Adult Oncology2022
2022 Impact of sociodemographic factors on early mortality in acute promyelocytic leukemia in the United States: A time-trend analysisCancer.  128:292-298. 2022
2022 Dismal survival outcomes of patients with acute myeloid leukemia after failure of venetoclax with hypomethylating agentsLeukemia and Lymphoma2022
2022 Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patientsLeukemia2022
2022 Risk of mortality and second malignancies in primary myelofibrosis before and after ruxolitinib approvalLeukemia Research.  112. 2022
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantationAmerican Journal of Hematology.  96:E396-E398. 2021
2021 Impact of insurance status on the survival of younger patients diagnosed with acute promyelocytic leukemia in the United StatesCancer.  127:2966-2973. 2021
2021 Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR (Leukemia, (2021), 35, 7, (2076-2085), 10.1038/s41375-021-01213-5)Leukemia.  35:2140. 2021
2021 Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRLeukemia.  35:2076-2085. 2021
2021 Survival of chronic myeloid leukemia patients in comparison to the general population in the tyrosine kinase inhibitors era: A US population-based studyAmerican Journal of Hematology.  96:E265-E268. 2021
2021 Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantationBone Marrow Transplantation.  56:1364-1372. 2021
2021 Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemiaLeukemia and Lymphoma.  62:2292-2294. 2021
2020 Usefulness of patient-reported outcomes to assess the effectiveness of topical hormonal therapy for gynecologic symptoms after antihormonal treatment for breast cancerBaylor University Medical Center Proceedings.  33:331-335. 2020
2020 Observation Versus Immediate Reinduction for Acute Myeloid Leukemia Patients With Indeterminate Day 14 Bone Marrow ResultsClinical Lymphoma, Myeloma and Leukemia.  20:31-38. 2020
2019 Acute promyelocytic leukemia during pregnancy: A case report and 10-year institutional review of hematologic malignancies during pregnancyPathology, Research and Practice.  215. 2019
2019 Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivorsLeukemia Research.  82:1-6. 2019
2018 Outcomes of fludarabine, high dose cytarabine and granulocyte-colony stimulating factor (FLAG) as re-induction for residual acute myeloid leukemia on day 14 bone marrowLeukemia Research.  74:64-67. 2018
2017 Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipelineExpert Opinion on Emerging Drugs.  22:347-355. 2017
2016 Under-recognition of hemophagocytic syndrome in United States’ rural, non-teaching hospitalsLeukemia and Lymphoma.  57:2911-2913. 2016
2016 Genomic alterations in neuroendocrine cancers of the ovaryJournal of Ovarian Research.  9. 2016
2016 Comorbidities Drive Outcomes for Both Malignancy-Associated and Non-Malignancy-Associated Hemophagocytic SyndromeClinical Lymphoma, Myeloma and Leukemia.  16:230-236. 2016
2015 How center volumes affect early outcomes in acute myeloid leukemiaClinical Lymphoma, Myeloma and Leukemia.  15:646-654. 2015
2015 Induction of acute myeloid leukemia with idarubicin, cytarabine and cladribineAnticancer Research: international journal of cancer research and treatment.  35:6287-6290. 2015
2015 Pleural epitheliod hemangioendothelioma: What started as a liver fluke and ended up being almost mistaken for malignant mesotheliomaAnnals of Thoracic Medicine.  10:289-291. 2015
2015 Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosisLeukemia Research.  39:1342-1346. 2015
2015 Influence of insurance and marital status on outcomes of adolescents and young adults with acute lymphoblastic leukemiaClinical Lymphoma, Myeloma and Leukemia.  15:364-367. 2015
2015 Population-based analysis of the clinical features of primary small cell carcinoma of the ovaryAnticancer Research: international journal of cancer research and treatment.  35:3091-3096. 2015
2015 Male breast cancer: A 24 year experience of a tertiary care Hospital in PakistanAsian Pacific Journal of Cancer Prevention (APJCP).  16:1559-1563. 2015
2014 New oral anticoagulants in patients with atrial fibrillation (1)The Lancet.  384:23-24. 2014
2013 Role of genetic counselling in prenatal diagnosis of β-thalassaemia in Pakistan.Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.  23:553-557. 2013
2011 Early complications after biliary enteric anastomosis for benign diseases: A retrospective analysisBMC Surgery.  11. 2011
2011 Clinical applications of the pedicled anterolateral thigh flap in penile reconstructionJournal of Plastic, Reconstructive and Aesthetic Surgery.  64:1075-1081. 2011

Investigator On

  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Predictors of Systemic Exposure to Oral 6MP During Maintenance in Adolescents and Young Adults with Acute Lymphoblastic Leukemia  awarded by National Cancer Institute/NIH/DHHS
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by CTI BIOPHARMA CORP
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC
  • Private Grant  awarded by SEATTLE GENETICS, INC.
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ONCOIMMUNE, INC.
  • Private Grant  awarded by FORTY SEVEN, INC.
  • Private Grant  awarded by AMGEN, INC.^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC. - NEW
  • Private Grant  awarded by TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
  • Private Grant  awarded by INCYTE CORPORATION
  • Private Grant  awarded by GlaxoSmithKline
  • Private Grant  awarded by BLUEPRINT MEDICINES CORPORATION
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by CELGENE CORPORATION
  • Private Grant  awarded by FATE THERAPEUTICS, INC.
  • Private Grant  awarded by SYNDAX PHARMACEUTICALS, INC.
  • Private Grant  awarded by KARTOS THERAPEUTICS INC.
  • Private Grant  awarded by CHIMERIX, INC.
  • Private Grant  awarded by DELTA-FLY PHARMA INC
  • Private Grant  awarded by MARKER THERAPEUTICS INC
  • Private Grant  awarded by CONSTELLATION PHARMACEUTICALS INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by Gilead Sciences ^
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by SYROS PHARMACEUTICALS INC.
  • Private Grant  awarded by PHARMAXIS
  • Private Grant  awarded by BLUEPRINT MEDICINES CORPORATION
  • Private Grant  awarded by ZENTALIS
  • Private Grant  awarded by IONIS PHARMACEUTICALS, INC.
  • Private Grant  awarded by APTOSE BIOSCIENCES INC.
  • Private Grant  awarded by ASTEX PHARMACEUTICALS
  • Private Grant  awarded by TELIOS PHARMA INC
  • Private Grant  awarded by COGENT BIOSCIENCES INC
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC.
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • UAB 19113: A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML  awarded by SOUTHERN RESEARCH INSTITUTE
  • Education And Training

  • Bachelor of Medicine & Surgery (MBBS), Aga Khan University 2012
  • Full Name

  • Omer Jamy